Home » July / August 2022 » Scientific due diligence builds better business relationships
2022 | July / August 2022

Scientific due diligence builds better business relationships

by cyb2025
D. Seimetz, J. Schneider

DIANE SEIMETZ1, JÖRG SCHNEIDER2
1.Principal Consultant
2. Associate Principal Consultant, Biopharma Excellence, Germany

ABSTRACT

The biopharma sector is seeing a proliferation of mergers, partnerships and acquisitions, but deals can sometimes fail due to poor scientific due diligence. Diane Seimetz and Jörg Schneider at Biopharma Excellence outline a plan of action to help you get the most from your business relationships.

Companies or individuals planning to go into business with others need to take a lot of care, especially when scientific, technical and regulatory information about complex therapeutic products is involved. For biotech companies and academic developers wishing to partner with larger firms, the process of assessing potential partners or licensing agreements is perhaps best regarded as a form of scientific due diligence. If done correctly, it will ensure that all parties are happy with the agreement. Whether your biotech company is looking at licensing products or technology platforms, or at an M&A or partnering agreement, you need to be able to show your value to potential partners and equity providers.

ABOUT THE AUTHOR

Diane Seimetz has over 22 years of international drug development, partnering and managerial experience in the biopharmaceutical industry. In 2013, she co-founded Biopharma Excellence and served as its Chief Executive Officer from December 2013 until June 2021. Biopharma Excellence was acquired by the PharmaLex Group in September 2020. Since July 2021, Dr. Seimetz has served as Principal Consultant at the PharmaLex Group.
Jörg Schneider is a translational biopharmaceutical expert with more than 20 years of experience in small to mid-size biotech companies. At Biopharma Excellence he focuses on ATMPs/CGT products and he is involved in regulatory interactions, nonclinical and strategic support for multiple clients. Jörg provides scientific, regulatory and strategic support for US-based and European clients based on his broad knowledge of different technologies and product classes.

Latest issue

November /December 2025

View Issue

Archive

For an even more in-depth scientific analysis, consult the archive

Chemistry Today - Archive
Go to archive

Content from magazine

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores.
View all content

Most popular

@2026 - All Right Reserved.

Login